IP Library › Patent Application 13923858
Patent Application
App. No. 13/923,858

QUINOLINE DERIVATIVE-CONTAINING PHARMACEUTICAL COMPOSITION

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
13/923,858
Abstract

A pharmaceutical composition comprising a compound represented by the formula (I) or pharmaceutically acceptable salt thereof or solvate thereof, and a basic substance is excellent in dissolution, is stable even after a long term storage, and is useful as a preventive or therapeutic agent against a tumor: wherein, R 1 is a hydrogen atom, a C 1-6 alkyl group or a C 3-8 cycloalkyl group; and R 2 is a hydrogen atom or a methoxy group.

Claims (21)

1 - 12 . (canceled)

13 . A pharmaceutical composition comprising 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide methanesulfonate and an alkaline earth metal carbonate.

14 . The pharmaceutical composition according to claim 13 , further comprising a disintegrating agent.

15 . The pharmaceutical composition according to claim 13 , wherein the alkaline earth metal carbonate is calcium carbonate.

16 . The pharmaceutical composition according to claim 15 , further comprising a disintegrating agent.

17 . The pharmaceutical composition according to claim 13 , wherein the alkaline earth metal carbonate is magnesium carbonate.

18 . The pharmaceutical composition according to claim 17 , further comprising a disintegrating agent.

19 . The pharmaceutical composition according to claim 14 , wherein the disintegrating agent is at least one agent selected from carmellose sodium, carmellose calcium, carboxymethyl starch sodium, croscarmellose sodium, low-substituted hydroxypropylcellulose and crospovidone.

20 . The pharmaceutical composition according to claim 13 , wherein said pharmaceutical composition is in a capsule dosage form.

21 . The pharmaceutical composition according to claim 15 , wherein said pharmaceutical composition is in a capsule dosage form.

22 . The pharmaceutical composition according to claim 17 , wherein said pharmaceutical composition is in a capsule dosage form.

23 . A pharmaceutical composition comprising:

4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide methanesulfonate; and

means for achieving dissolution of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide methanesulfonate.

24 . The pharmaceutical composition according to claim 23 , wherein said pharmaceutical composition is in a capsule dosage form.

25 . The pharmaceutical composition according to claim 23 , wherein said pharmaceutical composition is in a tablet dosage form.

26 . A pharmaceutical composition comprising:

4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide methanesulfonate; and

means for achieving dissolution of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide methanesulfonate at a dissolution rate that is higher than the dissolution rate of a composition identical to said pharmaceutical composition except lacking said means.

27 . The pharmaceutical composition according to claim 26 , wherein said pharmaceutical composition is in a capsule dosage form.

28 . The pharmaceutical composition according to claim 26 , wherein said pharmaceutical composition is in a tablet dosage form.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 2, 2013
From: BANDO, MASASHI
To: EISAI R&D MANAGEMENT CO., LTD.
Reel/Frame 030929/0886 →